Ronny Drapkin

List of Publications by Year
in descending order

156	22,717	15495 65	8618 146
papers	citations	h-index	g-index

170	170	170	25342
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Wholeâ€“genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	13.7	1,206
2	Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes and Development, 2005, 19, 489-501.	2.7	1,122
3	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	12.8	1,084
4	53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nature Structural and Molecular Biology, 2010, 17, 688-695.	3.6	846
5	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	12.8	839
6	A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Journal of Pathology, 2007, 211, 26-35.	2.1	783
7	Dual role of TFIIH in DNA excision repair and in transcription by RNA polymerase II. Nature, 1994, 368, 769-772.	13.7	725
8	The Ubiquitin Ligase Activity in the DDB2 and CSA Complexes Is Differentially Regulated by the COP9 Signalosome in Response to DNA Damage. Cell, 2003, 113, 357-367.	13.5	667
9	BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function. Cell, 2001, 105, 149-160.	13.5	606
10	High grade serous ovarian carcinomas originate in the fallopian tube. Nature Communications, 2017, 8, 1093.	5.8	515
11	Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy. Science, 2011, 334, 1129-1133.	6.0	502
12	Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models. Cancer Cell, 2013, 24, 751-765.	7.7	488
13	Human Epididymis Protein 4 (HE4) Is a Secreted Glycoprotein that Is Overexpressed by Serous and Endometrioid Ovarian Carcinomas. Cancer Research, 2005, 65, 2162-2169.	0.4	484
14	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation, 2013, 123, 517-25.	3.9	462
15	Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature, 1995, 374, 283-287.	13.7	430
16	The distal fallopian tube: a new model for pelvic serous carcinogenesis. Current Opinion in Obstetrics and Gynecology, 2007, 19, 3-9.	0.9	425
17	A recurrent mutation in PALB2 in Finnish cancer families. Nature, 2007, 446, 316-319.	13.7	402
18	A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors. American Journal of Surgical Pathology, 2011, 35, 816-826.	2.1	402

#	Article	IF	Citations
19	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12372-12377.	3.3	383
20	New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact. Journal of Clinical Oncology, 2008, 26, 5284-5293.	0.8	362
21	A human RNA polymerase II complex associated with SRB and DNA-repair proteins. Nature, 1996, 381, 86-89.	13.7	342
22	Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous Cancer. Clinical Medicine and Research, 2007, 5, 35-44.	0.4	301
23	Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy. Cell, 2015, 160, 977-989.	13.5	295
24	BRCA1 Supports XIST RNA Concentration on the Inactive X Chromosome. Cell, 2002, 111, 393-405.	13.5	283
25	The p400 Complex Is an Essential E1A Transformation Target. Cell, 2001, 106, 297-307.	13.5	282
26	Serous Carcinogenesis in the Fallopian Tube. International Journal of Gynecological Pathology, 2008, 27, 1-9.	0.9	275
27	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecologic Oncology, 2008, 109, 168-173.	0.6	268
28	Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7547-7552.	3.3	249
29	Pathogenesis and heterogeneity of ovarian cancer. Current Opinion in Obstetrics and Gynecology, 2017, 29, 26-34.	0.9	223
30	The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2357-2362.	3.3	215
31	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. Cancer Cell, 2010, 17, 298-310.	7.7	207
32	PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. Molecular Cell, 2015, 60, 571-583.	4.5	202
33	PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma. American Journal of Surgical Pathology, 2010, 34, 627-635.	2.1	201
34	Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene, 2010, 29, 1103-1113.	2.6	187
35	RNA polymerase II stalled at a thymine dimer: footprint and effect on excision repair. Nucleic Acids Research, 1997, 25, 787-793.	6.5	174
36	Where transcription meets repair. Cell, 1994, 77, 9-12.	13.5	169

#	Article	IF	Citations
37	Human cyclin-dependent kinase-activating kinase exists in three distinct complexes.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 6488-6493.	3.3	157
38	Targeted Tumor-Penetrating siRNA Nanocomplexes for Credentialing the Ovarian Cancer Oncogene ID4. Science Translational Medicine, 2012, 4, 147ra112.	5.8	157
39	Cyclin E1 Deregulation Occurs Early in Secretory Cell Transformation to Promote Formation of Fallopian Tubeâ€“Derived High-Grade Serous Ovarian Cancers. Cancer Research, 2014, 74, 1141-1152.	0.4	151
40	Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome. Clinical Cancer Research, 2012, 18, 5806-5815.	3.2	150
41	A Molecular Signature of Gastric Metaplasia Arising in Response to Acute Parietal Cell Loss. Gastroenterology, 2008, 134, 511-522.	0.6	146
42	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 232-237.	3.3	136
43	GATA3 Is a Sensitive and Specific Marker of Benign and Malignant Mesonephric Lesions in the Lower Female Genital Tract. American Journal of Surgical Pathology, 2015, 39, 1411-1419.	2.1	124
44	Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nature Protocols, 2012, 7, 1755-1764.	5.5	123
45	The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3259-3263.	3.3	118
46	Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Reports, 2016, 14, 429-439.	2.9	118
47	Mesenchymal gene programâ€“expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. Journal of Clinical Investigation, 2014, 124, 2611-2625.	3.9	110
48	Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer. PLoS ONE, 2012, 7, e30269.	1.1	107
49	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clinical Cancer Research, 2017, 23, 1862-1874.	3.2	107
50	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Reports, 2015, 13, 2395-2402.	2.9	105
51	It's Totally Tubularâ€¦ Riding The New Wave of Ovarian Cancer Research. Cancer Research, 2016, 76, 10-17.	0.4	105
52	Regulation of RNA polymerase II transcription. Current Opinion in Cell Biology, 1993, 5, 469-476.	2.6	102
53	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clinical Cancer Research, 2017, 23, 1263-1273.	3.2	95
54	Distinctive Cytogenetic Profile in Benign Metastasizing Leiomyoma: Pathogenetic Implications. American Journal of Surgical Pathology, 2007, 31, 737-743.	2.1	94

#	Article	IF	Citations
55	Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology, 2008, 53, 127-138.	1.6	89
56	The multifunctional TFIIH complex and transcriptional control. Trends in Biochemical Sciences, 1994, 19, 504-508.	3.7	87
57	Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecologic Oncology, 2012, 124, 270-275.	0.6	85
58	Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecologic Oncology, 2011, 123, 5-12.	0.6	82
59	Tumor innervation: peripheral nerves take control of the tumor microenvironment. Journal of Clinical Investigation, 2021, 131, .	3.9	79
60	Purification of human RNA polymerase II and general transcription factors. Methods in Enzymology, 1996, 274, 72-100.	0.4	78
61	Regression of Drug-Resistant Lung Cancer by the Combination of Rosiglitazone and Carboplatin. Clinical Cancer Research, 2008, 14, 6478-6486.	3.2	77
62	Coming into focus: the nonovarian origins of ovarian cancer. Annals of Oncology, 2013, 24, viii28-viii35.	0.6	75
63	PRKCI promotes immune suppression in ovarian cancer. Genes and Development, 2017, 31, 1109-1121.	2.7	75
64	Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines. Cell Reports, 2018, 25, 2617-2633.	2.9	74
65	Further Evidence for BRCA1 Communication with the Inactive X Chromosome. Cell, 2007, 128, 991-1002.	13.5	72
66	CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Modern Pathology, 2016, 29, 1254-1261.	2.9	72
67	CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nature Communications, 2018, 9, 631.	5.8	72
68	Expression of candidate tumor markers in ovarian carcinoma and benign ovary: Evidence for a link between epithelial phenotype and neoplasia. Human Pathology, 2004, 35, 1014-1021.	1.1	69
69	Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research. Gynecologic Oncology, 2015, 139, 97-103.	0.6	65
70	TGFBI Production by Macrophages Contributes to an Immunosuppressive Microenvironment in Ovarian Cancer. Cancer Research, 2021, 81, 5706-5719.	0.4	64
71	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
72	YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene, 2016, 35, 2247-2265.	2.6	63

#	Article	IF	Citations
73	Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clinical Cancer Research, 2015, 21, 4960-4969.	3.2	62
74	HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. International Journal of Molecular Sciences, 2013, 14, 6026-6043.	1.8	61
75	A Novel Breast Cancerâ€“Associated BRIP1 (FANCJ/BACH1) Germ-line Mutation Impairs Protein Stability and Function. Clinical Cancer Research, 2008, 14, 4672-4680.	3.2	56
76	Overexpression of Elafin in Ovarian Carcinoma Is Driven by Genomic Gains and Activation of the Nuclear Factor ÎºB Pathway and Is Associated with Poor Overall Survival. Neoplasia, 2010, 12, 161-IN15.	2.3	56
77	Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle. Clinical Cancer Research, 2015, 21, 4410-4419.	3.2	55
78	Combined therapy with thrombospondinâ€1 type I repeats (3TSR) and chemotherapy induces regression and significandy improves survival in a preclinical model of advanced stage epithelial ovarian cancer. FASEB Journal, 2015, 29, 576-588.	0.2	55
79	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight, 2017, 2, e89760.	2.3	55
80	Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective. Histopathology, 2009, 55, 619-619.	1.6	54
81	Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Science Translational Medicine, 2016, 8, 329ra34.	5.8	54
82	Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy. Oncogenesis, 2017, 6, e295-e295.	2.1	54
83	A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology, 2018, 149, 585-591.	0.6	53
84	The hormonal composition of follicular fluid and its implications for ovarian cancer pathogenesis. Reproductive Biology and Endocrinology, 2014, 12, 60.	1.4	52
85	Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. OncoImmunology, 2016, 5, e1090075.	2.1	50
86	Innervation of cervical carcinoma is mediated by cancer-derived exosomes. Gynecologic Oncology, 2019, 154, 228-235.	0.6	50
87	Stathmin 1 and p16INK4A are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma. Gynecologic Oncology, 2015, 139, 104-111.	0.6	47
88	CD151-Î±3Î²1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling. Oncotarget, 2014, 5, 12203-12217.	0.8	47
89	Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming. Nature Communications, 2020, 11, 2717.	5.8	45
90	Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight, 2016, 1, .	2.3	45

#	Article	IF	Citations
91	High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary. PLoS ONE, 2011, 6, e24433.	1.1	44
92	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Communications, 2017, 8, 365.	5.8	44
93	In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1102-1107.	3.3	42
94	Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene, 2015, 34, 373-383.	2.6	42
95	Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI Insight, 2016, 1, .	2.3	42
96	Tumor Innervation: Cancer Has Some Nerve. Trends in Cancer, 2020, 6, 1059-1067.	3.8	41
97	Adenofibroma of the Fimbria: A Common Entity That Is Indistinguishable From Ovarian Adenofibroma. International Journal of Gynecological Pathology, 2008, 27, 390-397.	0.9	40
98	Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms. Frontiers in Oncology, 2013, 3, 217.	1.3	40
99	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	1.4	40
100	<scp>GATA</scp>3 expression in gestational trophoblastic tissues and tumours. Histopathology, 2015, 67, 636-644.	1.6	39
101	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patientâ€“Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Molecular Cancer Therapeutics, 2019, 18, 642-655.	1.9	39
102	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.	2.0	39
103	Role of miR-182 in response to oxidative stress in the cell fate of human fallopian tube epithelial cells. Oncotarget, 2015, 6, 38983-38998.	0.8	38
104	Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer. Cell Reports, 2017, 18, 2343-2358.	2.9	38
105	Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer. Cancer Research, 2019, 79, 760-772.	0.4	38
106	Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas. Human Pathology, 2013, 44, 734-742.	1.1	37
107	Association of BRCA1 with the inactive X chromosome and XIST RNA. Philosophical Transactions of the Royal Society B: Biological Sciences, 2004, 359, 123-128.	1.8	36
108	Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer, 2021, 2, 189-200.	5.7	36

#	Article	IF	Citations
109	CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer. Scientific Reports, 2018, 8, 14725.	1.6	35
110	HE4 Transcription- and Splice Variants-Specific Expression in Endometrial Cancer and Correlation with Patient Survival. International Journal of Molecular Sciences, 2013, 14, 22655-22677.	1.8	31
111	Predicting master transcription factors from pan-cancer expression data. Science Advances, 2021, 7, eabf6123.	4.7	30
112	Stathmin-1 Expression as a Complement to p16 Helps Identify High-grade Cervical Intraepithelial Neoplasia With Increased Specificity. American Journal of Surgical Pathology, 2013, 37, 89-97.	2.1	29
113	FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene, 2014, 33, 4424-4432.	2.6	29
114	Use of Yeast-SecretedIn vivoBiotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISA. Clinical Cancer Research, 2008, 14, 2647-2655.	3.2	28
115	Promoter methylation of the SALL2 tumor suppressor gene inÂovarian cancers. Molecular Oncology, 2013, 7, 419-427.	2.1	28
116	Endosalpingiosis as it relates to tubal, ovarian and serous neoplastic tissues: An immunohistochemical study of tubal and MÃ¼llerian antigens. Gynecologic Oncology, 2014, 132, 316-321.	0.6	28
117	In vivoÂmodeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genetics, 2020, 16, e1008808.	1.5	27
118	Testing ovarian cancer cell lines to train dogs to detect ovarian cancer from blood plasma: A pilot study. Journal of Veterinary Behavior: Clinical Applications and Research, 2019, 32, 42-48.	0.5	26
119	Aberrant Expression of the Dendritic Cell Marker TNFAIP2 by the Malignant Cells of Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma Distinguishes These Tumor Types From Morphologically and Phenotypically Similar Lymphomas. American Journal of Surgical Pathology, 2011, 35, 1531-1539.	2.1	25
120	Immunoaffinity Purification of the Human Multisubunit Transcription Factor IIH. Journal of Biological Chemistry, 1998, 273, 7134-7140.	1.6	24
121	The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecologic Oncology, 2012, 124, 185-191.	0.6	24
122	Precious GEMMs: emergence of faithful models for ovarian cancer research. Journal of Pathology, 2018, 245, 129-131.	2.1	24
123	miR-181a initiates and perpetuates oncogenic transformation through the regulation of innate immune signaling. Nature Communications, 2020, 11, 3231.	5.8	24
124	The SETDB1â€“TRIM28 Complex Suppresses Antitumor Immunity. Cancer Immunology Research, 2021, 9, 1413-1424.	1.6	24
125	Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1383-1393.	1.1	23
126	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Journal of Pathology, 2018, 246, 459-469.	2.1	23

#	Article	IF	Citations
127	Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells. Journal of Visualized Experiments, 2011, , .	0.2	21
128	Expression of the POTE gene family in human ovarian cancer. Scientific Reports, 2018, 8, 17136.	1.6	21
129	SUSD2 expression in high-grade serous ovarian cancer correlates with increased patient survival and defective mesothelial clearance. Oncogenesis, 2016, 5, e264-e264.	2.1	20
130	The Polyoma Virus Large T Binding Protein p150 Is a Transcriptional Repressor of c-MYC. PLoS ONE, 2012, 7, e46486.	1.1	19
131	CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary. Cancers, 2019, 11, 1710.	1.7	18
132	Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecologic Oncology, 2014, 132, 328-333.	0.6	17
133	Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma. Cancer Research, 2019, 79, 5536-5549.	0.4	17
134	The new face of ovarian cancer modeling: better prospects for detection and treatment. F1000 Medicine Reports, 2011, 3, 22.	2.9	15
135	The transcription factor PAX8 promotes angiogenesis in ovarian cancer through interaction with SOX17. Science Signaling, 2022, 15, eabm2496.	1.6	15
136	Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers. Cancer Research, 2021, 81, 806-810.	0.4	14
137	Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight, 2020, 5, .	2.3	13
138	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 132-141.	1.1	12
139	Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube?. Fertility and Sterility, 2008, 90, 2008.e5-2008.e8.	0.5	11
140	Deubiquitinase UCHL1 Maintains Protein Homeostasis through the PSMA7â€“APEHâ€“Proteasome Axis in High-grade Serous Ovarian Carcinoma. Molecular Cancer Research, 2021, 19, 1168-1181.	1.5	11
141	The tubal epigenome â€“ An emerging target for ovarian cancer. , 2020, 210, 107524.		10
142	Intra-Tumoral Nerve-Tracing in a Novel Syngeneic Model of High-Grade Serous Ovarian Carcinoma. Cells, 2021, 10, 3491.	1.8	10
143	Unilateral Transverse Arm Defect with Subterminal Digital Nubbins. Pediatric and Developmental Pathology, 2003, 6, 348-354.	0.5	9
144	A candidate precursor to serous carcinoma that originates in the distal fallopian tube (J Pathol 2007;) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.1	7

#	Article	IF	Citations
145	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prevention Research, 2016, 9, 713-720.	0.7	7
146	Urokinase-Type Plasminogen Activator Receptor: A Beacon of Malignancy?. Clinical Cancer Research, 2008, 14, 5643-5645.	3.2	6
147	KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. Cancer Immunology Research, 2022, 10, 1028-1038.	1.6	6
148	The essential twist. Nature, 1994, 369, 523-524.	13.7	4
149	Flower lose, a cell fitness marker, predicts COVIDâ€19 prognosis. EMBO Molecular Medicine, 2021, 13, e13714.	3.3	4
150	An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells. Cancer Cell, 2010, 17, 412.	7.7	3
151	Cell Fitness: More Than Push-Ups. International Journal of Molecular Sciences, 2021, 22, 518.	1.8	3
152	There is a need for routine peritoneal cytology at RRSO. Gynecologic Oncology, 2013, 128, 149-150.	0.6	1
153	Elafin: a double agent in breast and ovarian cancer. Oncoscience, 2015, 2, 793-794.	0.9	1
154	Cancers Arising in the Ovary. , 2014, , 1592-1613.e6.		1
155	PAX8 and lineage dependence in high grade serous ovarian cancer. Gynecologic Oncology, 2015, 139, 591-592.	0.6	0
156	Primordial germ cell as potent cell of origin of mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Annals of Oncology, 2016, 27, vi548.	0.6	0